US EditionPublished • loading... • Updated
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Summary by 247wallst.com
1 Articles
1 Articles
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
Quick Read Pfizer (PFE) posted Q3 revenue of $16.65B down 5.9% as COVID products declined sharply. Paxlovid dropped 55% and Comirnaty fell 20%. Teva (TEVA) delivered its 11th consecutive quarter of growth with revenue up 3.4% to $4.48B. AUSTEDO surged 38% to $618M and drove the innovative portfolio expansion. Teva crushed EPS estimates by 16% at $0.78 versus $0.67 consensus. Pfizer beat by 36% but still faces contraction across its core busin…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
